Adjuvant Sunitinib in Renal-Cell Carcinoma

被引：4
|
作者：
Zhang, Sheng [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 09期
关键词：
RISK;
D O I：
10.1056/NEJMc1616636
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：893 / 893
页数：1
相关论文
共 50 条
  • [31] Re: Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma
    Flanigan, Robert C.
    EUROPEAN UROLOGY, 2019, 75 (05) : 876 - 877
  • [32] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    Szczylik, Cezary
    Markus, Maurice
    McDermott, Raymond S.
    Bedke, Jens
    Tartas, Sophie
    Chang, Yen-Hwa
    Tamada, Satoshi
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
  • [33] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Frontera, O. Aren
    Melichar, B.
    Choueiri, T. K.
    Plimack, Elizabeth R.
    Barthelemy, P.
    Porta, C.
    George, S.
    Powles, T.
    Donskov, F.
    Neiman, V.
    Kollmannsberger, C. K.
    Salman, P.
    Gurney, H.
    Hawkins, R.
    Ravaud, A.
    Grimm, M. -O.
    Bracarda, S.
    Barrios, C. H.
    Tomita, Y.
    Castellano, D.
    Rini, B. I.
    Chen, A. C.
    Mekan, S.
    McHenry, M. B.
    Wind-Rotolo, M.
    Doan, J.
    Sharma, P.
    Hammers, H. J.
    Escudier, B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14): : 1277 - 1290
  • [34] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
  • [35] Adjuvant therapy in renal-cell carcinoma: Is it prime time yet?
    Dimitriadis, John
    Bamias, Aristotelis
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S360 - S362
  • [36] Re: Overall Survival with Adjuvant Pembrolizumab in Renal-cell Carcinoma
    Liu, Zhenbang
    AlSaffar, Haidar
    Perera, Sachin
    Mazzone, Elio
    Lawrentschuk, Nathan
    Eapen, Renu
    Murphy, Declan G.
    Perera, Marlon L.
    EUROPEAN UROLOGY, 2024, 86 (05) : 482 - 483
  • [37] Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma
    Magee, Diana E.
    Kutikov, Alexander
    EUROPEAN UROLOGY, 2022, 81 (03) : 317 - 318
  • [38] Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature
    Bandini, Marco
    Smith, Ariane
    Marchioni, Michele
    Pompe, Raisa S.
    Martel, Tristan F.
    Cindolo, Luca
    Montorsi, Francesco
    Shariat, Shahrokh F.
    Briganti, Alberto
    Kapoor, Anil
    Capitanio, Umberto
    Karakiewicz, Pierre I.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : 176 - 183
  • [39] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma REPLY
    Choueiri, Toni K.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (20): : 1920 - 1920
  • [40] ADJUVANT CHEMOTHERAPY WITH VINBLASTINE, ADRIAMYCIN, AND UFT FOR RENAL-CELL CARCINOMA
    MASUDA, F
    NAKADA, J
    KONDO, I
    FURUTA, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (06) : 477 - 479
12345